Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Revenue (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Revenue for 7 consecutive years, with $114.1 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 279.52% to $114.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $139.7 million through Dec 2025, up 120.01% year-over-year, with the annual reading at $139.7 million for FY2025, 120.01% up from the prior year.
  • Revenue for Q4 2025 was $114.1 million at Beam Therapeutics, up from $9.7 million in the prior quarter.
  • The five-year high for Revenue was $316.2 million in Q4 2023, with the low at $6000.0 in Q1 2021.
  • Average Revenue over 5 years is $34.7 million, with a median of $15.0 million recorded in 2022.
  • The sharpest move saw Revenue skyrocketed 851050.0% in 2021, then crashed 90.49% in 2024.
  • Over 5 years, Revenue stood at $51.1 million in 2021, then plummeted by 60.76% to $20.0 million in 2022, then soared by 1478.04% to $316.2 million in 2023, then plummeted by 90.49% to $30.1 million in 2024, then skyrocketed by 279.52% to $114.1 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $114.1 million, $9.7 million, and $8.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.